{
    "paperId": "aa0d1af96bb263cabcaa23a44c8d3d160b0b63e3",
    "externalIds": {
        "MAG": "2137271428",
        "DOI": "10.1016/j.jaad.2014.05.020",
        "CorpusId": 27277386,
        "PubMed": "24929884"
    },
    "title": "An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.",
    "abstract": null,
    "venue": "Journal of American Academy of Dermatology",
    "year": 2014,
    "referenceCount": 19,
    "citationCount": 140,
    "influentialCitationCount": 4,
    "openAccessPdf": null,
    "tldr": {
        "model": "tldr@v2.0.0",
        "text": "Neoadjuvant vismodegib appears to reduce surgical defect area when taken for 3 months or longer for nonrecurrent BCCs in functionally sensitive locations, and this was an open-label, single-arm intervention trial."
    },
    "embedding": null,
    "authors": [
        {
            "authorId": "4736013",
            "name": "M. Ally"
        },
        {
            "authorId": "6216726",
            "name": "S. Aasi"
        },
        {
            "authorId": "4725636",
            "name": "A. Wysong"
        },
        {
            "authorId": "15100499",
            "name": "C. Teng"
        },
        {
            "authorId": "1396324448",
            "name": "E. Anderson"
        },
        {
            "authorId": "1399850735",
            "name": "I. Bailey-Healy"
        },
        {
            "authorId": "5377728",
            "name": "A. Oro"
        },
        {
            "authorId": "2109178884",
            "name": "Jinah Kim"
        },
        {
            "authorId": "145055574",
            "name": "A. Chang"
        },
        {
            "authorId": "2220128246",
            "name": "Jean Y. Tang"
        }
    ],
    "references": [
        {
            "paperId": "b812551f12ed6769f939e4783dbf210ee120daf2",
            "title": "Histologic changes in basal cell carcinoma after treatment with vismodegib."
        },
        {
            "paperId": "99e54f1beb4454c76299b06cdb7f279fc96d420c",
            "title": "Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma."
        },
        {
            "paperId": "535928f097a5d0030d82e66c1b0876055888eb2f",
            "title": "Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome."
        },
        {
            "paperId": "d66bbf175f0c77ec2c77f0515f8aaac4615eb127",
            "title": "Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011."
        },
        {
            "paperId": "8802b6d09f31cc072b88a80e69004199ab986e73",
            "title": "Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient."
        },
        {
            "paperId": "61f91b7b5bfa48f093400de19f67a97f5962def2",
            "title": "Nonmelanoma skin cancer of the head and neck: surgical treatment."
        },
        {
            "paperId": "08a128f37de3106791e8e3d9992ab9eb0d55541f",
            "title": "Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study"
        },
        {
            "paperId": "e24adc7f18ebbc23a92a3ad4369f40e2cdc1f547",
            "title": "Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome."
        },
        {
            "paperId": "7013b9f6f1aa06ec65850a619ed6118262b52953",
            "title": "Efficacy and safety of vismodegib in advanced basal-cell carcinoma."
        },
        {
            "paperId": "bfd7b98398b72d0acc706bb5317b453c0544a086",
            "title": "5-year recurrence rates of Mohs micrographic surgery for aggressive and recurrent facial basal cell carcinoma."
        },
        {
            "paperId": "aaa1f9a54e8bb51518605d4ae3afbffa4e4a1ee0",
            "title": "What Is the Best Surgical Margin for a Basal Cell Carcinoma: A Meta-Analysis of the Literature"
        },
        {
            "paperId": "fa99b87551c2318901e4f227fd68e4d3088ec5d3",
            "title": "Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans."
        },
        {
            "paperId": "24ba0f7e0afd82607e7d42da1b2a072915c0d7b9",
            "title": "Basal cell carcinomas: attack of the hedgehog"
        },
        {
            "paperId": "f380d71d05728aa1b6b5ac29e1f48f6fb44e481a",
            "title": "Curettage prior to Mohs' Micrographic Surgery for Previously Biopsied Nonmelanoma Skin Cancers: What Are We Curetting? Retrospective, Prospective, and Comparative Study"
        },
        {
            "paperId": "60b6221864a5bd0f36fdaf79f6cc0eaac8a3720e",
            "title": "Mohs' micrographic surgery for treatment of basal cell carcinoma of the face\u2014\u2014results of a retrospective study and review of the literature"
        },
        {
            "paperId": "599357d56dc56fc6ae93f0dc5552cc47d141fe72",
            "title": "Correlation of histologic subtypes of primary basal cell carcinoma and number of Mohs stages required to achieve a tumor-free plane."
        },
        {
            "paperId": "ffde6bc6d396941732b10255fd24de3434c3fb72",
            "title": "Nonmelanoma skin cancer in the United States: incidence."
        },
        {
            "paperId": "4e2e7e68abb8e1b461221db60c60c385d52ce5fb",
            "title": "Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up."
        },
        {
            "paperId": "d4fe7bc05f8ad076e8e8821a96ad42c8b1e9a2e6",
            "title": "Infiltrative basal cell carcinoma: a nonsclerosing subtype."
        }
    ]
}